The MAGPIE Study: Multi-cancer genomic risk assessment to target screening in general practice

Not Applicable

Completed

• Conditions: Breast Cancer; Bowel Cancer; Prostate Cancer; Melanoma; Breast cancer screening; Bowel cancer screening; Prostate cancer screening; Skin cancer screening; Cancer - Breast; Cancer - Malignant melanoma

• Registration Number: ACTRN12623000053628
• Lead Sponsor: niversity of Melbourne

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-01-17
• Study Completion: 2024-02-10
• Last Update Posted: 29 July 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 149

Inclusion Criteria

Potential participants are those seeing a consented GP at the recruited clinics who meet all of the following criteria:
•Are aged between 45 and 59 years
•Are able to read and write English and competent to give informed consent
•Are contactable over the next six months for the study follow-up

Exclusion Criteria

- Have been diagnosed with any of breast, prostate, colorectal cancer or melanoma;
- Have any alarm symptoms that are indicative of the cancers included in the risk assessment:
Once or more and uninvestigated:
- Blood in stool or urine
oFor more than four weeks and uninvestigated:
- Problems with urination
- Diarrhoea
- Unexplained weight loss
- An unusual pain, lump or swelling anywhere in your body
- A new or changed spot on your skin;

- Have a known genetic predisposition to any of the four cancers in question or, a first-/second-degree relative with a genetic predisposition and the participants has not had genetic testing themselves. This is defined by a mutation in any of the following genes:
- CRC: Lynch syndrome (MLH1, PMS2, MSH2, MSH6, EPCAM), familial adenomatous polyposis (APC);
- BrCa: BRCA1, BRCA2, PALB2, ATM, CHEK2;
- PrCa: BRCA1, BRCA2, HOXB13;
- Melanoma: CDKN2A/p16.

Study & Design

• Study Type: Interventional
• Study Design: Not specified